Details of the Drug Formulations

General Information of Drug (ID: DMSFK9V)

Drug Name
Daclatasvir Drug Info
Synonyms
1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Approved [1]
Cross-matching ID
PubChem CID
25154714
ChEBI ID
CHEBI:82977
CAS Number
1009119-64-5
TTD ID
D09SGV
VARIDT ID
DR00144
INTEDE ID
DR0406
ACDINA ID
D00164

Full List of Drug Formulations Containing This Drug

Daclatasvir 30 mg tablet
Company Formulation ID FDA Description
E.R. Squibb & Sons F05204 Anhydrous lactose; Fd&c blue no. 2; Indigotindisulfonate sodium; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Polyethylene glycol 400; Silicon dioxide; Aluminum oxide; Hypromellose, unspecified; Microcrystalline cellulose
------------------------------------------------------------------------------------
Daclatasvir 60 mg tablet
Company Formulation ID FDA Description
E.R. Squibb & Sons F05205 Anhydrous lactose; Fd&c blue no. 2; Indigotindisulfonate sodium; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Polyethylene glycol 400; Silicon dioxide; Aluminum oxide; Hypromellose, unspecified; Microcrystalline cellulose
------------------------------------------------------------------------------------
Daclatasvir 90 mg tablet
Company Formulation ID FDA Description
E.R. Squibb & Sons F05206 Anhydrous lactose; Fd&c blue no. 2; Indigotindisulfonate sodium; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Polyethylene glycol 400; Silicon dioxide; Aluminum oxide; Hypromellose, unspecified; Microcrystalline cellulose
------------------------------------------------------------------------------------
Daclatasvir Dihydrochloride eq 30mg base tablet
Company Formulation ID FDA Description
Bristol-Myers Squibb F23954 Anhydrous Lactose; Microcrystalline Cellulose; Croscarmellose Sodium; Silicon Dioxide; Magnesium Stearate; Opadry Green
------------------------------------------------------------------------------------
Daclatasvir Dihydrochloride eq 60mg base tablet
Company Formulation ID FDA Description
Bristol-Myers Squibb F23955 Anhydrous Lactose; Microcrystalline Cellulose; Croscarmellose Sodium; Silicon Dioxide; Magnesium Stearate; Opadry Green
------------------------------------------------------------------------------------
Daclatasvir Dihydrochloride eq 90mg base tablet
Company Formulation ID FDA Description
Bristol-Myers Squibb F23956 Anhydrous Lactose; Microcrystalline Cellulose; Croscarmellose Sodium; Silicon Dioxide; Magnesium Stearate; Opadry Green
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.